News & Updates

Research findings from Yonsei Cancer Center in South Korea, presented at European Society for Medical Oncology Targeted Anticancer Therapies Asia Congress (ESMO TAT Asia) 2025, suggest a correlation between butyrate-producing Faecalibacterium enrichment and clinical response to pembrolizumab with or without chemotherapy in treatment-naïve patients with metastatic non-small-cell lung cancer (mNSCLC).

Adjuvant chemoradiotherapy (CRT) improves both 10-year overall survival (OS) and recurrence-free survival (RFS) in women with high-risk endometrial cancer vs pelvic radiotherapy alone, with the most clinically relevant benefit observed in p53 abnormal cancers, according to the 10-year analysis of the phase III PORTEC-3 trial.